Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2026-02-27 | Reverse | 1:30 |
| 2023-11-30 | Reverse | 1:4 |
Incannex Healthcare Limited develops and sells pharmaceutical-grade cannabinoid products in Australia, including clinical-stage treatments for sleep apnea, brain injury, and inflammatory conditions, through partnerships with hospitals and research...

IHL-42X, Incannex's lead investigational oral drug combining dronabinol and acetazolamide for obstructive sleep apnea, is in Phase 2/3 trials with FDA Fast Track designation.
Overall rating: B
| PEER | PRICE | |
|---|---|---|
AGEN | $7.66 | COMPARE |
IRD | $3.69 | COMPARE |
TTRX | $9.84 | COMPARE |
LUCD | $0.99 | COMPARE |
SEER | $1.98 | COMPARE |
CGTX | $1.02 | COMPARE |
ZYBT | $1.73 | COMPARE |
SCLX | $5.43 | COMPARE |